A 61-Year-Old Woman With Locally Advanced Pancreatic Adenocarcinoma Managed With Neoadjuvant FOLFIRINOX, Total Pancreatectomy, Splenectomy, Portal Vein and Common Hepatic Artery Resection, and Combined Vascular Reconstruction Using Splenic Artery Transposition: A Case Report.

Am J Case RepOct 29, 2026 (epub)

Javier Chapochnick, Carlos Derosas, Juan Alejandro Gonzalez

✦ AI-curated · Sources linked

Case in brief

A 61-year-old woman presented with progressive jaundice and CA 19-9 of 210 U/mL. Biopsy confirmed pancreatic ductal adenocarcinoma, and imaging showed portal vein and common hepatic artery involvement without distant metastases. After 12 cycles of FOLFIRINOX, vascular involvement persisted. She underwent total pancreatectomy and splenectomy with resection of a 4-cm portal vein segment and the common hepatic artery. Portal flow was restored by end-to-end anastomosis, and hepatic arterial inflow by splenic artery transposition. Pathology showed a 1.3-cm tumour, 2 of 41 involved nodes, and negative margins. A chylous fistula was managed; a pulmonary metastasis was resected at 15 months. She died from severe pneumonia 27 months after surgery, without locoregional recurrence.

What made this case unusual

The operation combined portal vein and common hepatic artery resection during total pancreatectomy, with portal venous end-to-end anastomosis and splenic artery transposition to restore hepatic arterial inflow.

Diagnostic / clinical pearl

In selected locally advanced pancreatic adenocarcinoma with major vascular involvement and no distant metastases, this report demonstrates a reconstructive approach combining portal vein anastomosis with splenic artery transposition after arterial resection.

Source

Published in Am J Case Rep. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in General Surgery

Clinical ResearchOncology (Medical)

Curative-intent management of de novo metastatic nasopharyngeal carcinoma: an evidence-based consensus guideline from the International Collaborating Oncology Organisations.

This international consensus guideline addresses curative-intent management of de novo metastatic nasopharyngeal carcinoma, a population historically treated with palliative intent.

Lancet OncolOct 29, 2026Read summary
Clinical ResearchHematology

Decitabine plus busulfan-cyclophosphamide versus busulfan-cyclophosphamide myeloablative conditioning before allogeneic haematopoietic stem cell transplantation for reducing risk of relapse in adult KMT2A‑rearranged leukaemia in China: an open-label, multicentre, randomised phase 3 trial.

This open-label, multicentre, randomised phase 3 trial compared decitabine plus busulfan-cyclophosphamide (DAC-BuCy) with BuCy conditioning before allogeneic HSCT in 130 patients aged 14–65 years with KMT2A-rearranged…

Lancet HaematolOct 30, 2026Read summary
Clinical ResearchPediatrics

Prone positioning and high-frequency oscillatory ventilation in early paediatric acute respiratory distress syndrome (PROSpect): an international, two-by-two factorial, response-adaptive, phase 3, randomised controlled trial.

PROSpect was an international, two-by-two factorial, phase 3 randomised controlled trial comparing prone with supine positioning and high-frequency oscillatory ventilation (HFOV) with conventional mechanical ventilation…

LancetOct 30, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.